Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3876602 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3876602 | EXPERIMENTAL | Single ascending doses of LY3876602 administered intravenously (IV). |
| Placebo | PLACEBO_COMPARATOR | Placebo administered IV. |
| LY3876602 Part B (MAD) | EXPERIMENTAL | Multiple ascending doses of LY3876602 will be administered intravenously (IV). |
| Placebo: Part B (MAD) | PLACEBO_COMPARATOR | Placebo administered IV |
| Name | Type | Description |
|---|---|---|
| LY3876602 | DRUG | Administered IV. |
| Placebo | DRUG | Administered IV. |
Inclusion Criteria: * Male and female participants who are overtly healthy as determined by medical evaluation * Have a body mass index with the range of 18 and less than or equal to (≤) 32 kilograms per square meter (kg/m²) * Male or female participants of nonchildbearing potential Exclusion Crit...
LY3876602 is an investigational small molecule being developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy adult participants. The specific disease or condition it is intended to treat has not been disclosed.
LY3876602 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly conducted the Phase 1 study of the compound in healthy volunteers.
LY3876602 is in Phase 1 clinical development. Its single Phase 1 trial, a single and multiple ascending dose study in healthy participants, has been completed. The drug remains investigational and has not been approved by the FDA.
LY3876602 has been evaluated in one clinical trial, NCT06007638, titled A Single and Multiple Ascending Dose Study of LY3876602 in Healthy Participants. The Phase 1 trial enrolled 74 healthy adults in the Netherlands and is completed.
The Phase 1 trial NCT06007638 was a randomized, double-blind, placebo-controlled study of single and multiple ascending doses of LY3876602. It enrolled 74 healthy participants aged 18 years and older in the Netherlands and has been completed.